Market Place
Sourcing Support
Repare Therapeutics Partners with NCI to Develop Camonsertib
12 Nov 2024 //
BUSINESSWIRE
Repare Therapeutics Business Update & Reports Q3 Financial Results
07 Nov 2024 //
BUSINESSWIRE
Repare Therapeutics Updates Safety Results from MYTHIC Trial
23 Oct 2024 //
BUSINESSWIRE
Repare Therapeutics Doses First Patient In RP-3467 Trial
14 Oct 2024 //
BUSINESSWIRE
Repare Therapeutics Presents Ph 1 Data For Camonsertib At ASTRO
30 Sep 2024 //
BUSINESSWIRE
Repare Therapeutics To Present Camonsertib Data At ESMO Congress 2024
13 Sep 2024 //
BUSINESSWIRE
Repare Cuts Preclinical R&D And 25% Staff To Focus On Key Candidates
29 Aug 2024 //
FIERCE BIOTECH
Repare Therapeutics Provides Business and Reports 2nd Quarter 2024
06 Aug 2024 //
BUSINESSWIRE
Repare Therapeutics shows Positive Data From Phase 1 MINOTAUR Trial At ESMO GI
26 Jun 2024 //
BUSINESSWIRE
Foundation Medicine, Repare Partner On Genomic Profiling, Companion Dx
12 Jun 2024 //
BUSINESSWIRE
Repare Doses First Patient In Camonsertib Non-Small Cell Lung Cancer Trial
10 Jun 2024 //
BUSINESSWIRE
Repare Therapeutics: FDA Granted Fast Track For Lunresertib+Camonsertib
04 Jun 2024 //
BUSINESSWIRE
Repare To Participate In Goldman Sachs Healthcare Conference
03 Jun 2024 //
BUSINESSWIRE
Repare Presents Initial MINOTAUR Phase 1 Data At ESMO GI 2024
29 May 2024 //
BUSINESSWIRE
Repare Provides Update, Q1 2024 Results
07 May 2024 //
BUSINESSWIRE
Repare, Debiopharm Dose First Patient In MYTHIC Combo Trial
30 Apr 2024 //
BUSINESSWIRE
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
26 Apr 2024 //
BUSINESSWIRE
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
29 Feb 2024 //
PRESS RELEASE
Repare Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
15 Feb 2024 //
PRESS RELEASE
Roche walks away from Repare solid tumor deal
13 Feb 2024 //
ENDPTS
Repare Therapeutics to Regain Global Rights to Camonsertib
12 Feb 2024 //
BUSINESSWIRE
Repare Announces Achievement of $40 Million Roche Clinical Milestone Payment
25 Jan 2024 //
BUSINESSWIRE
Repare Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
08 Jan 2024 //
BUSINESSWIRE
Debiopharm and Repare Therapeutics Partner to Explore PKMYT1 and WEE1
04 Jan 2024 //
BUSINESSWIRE
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
29 Dec 2023 //
BUSINESSWIRE
Repare Unveils Two Programs Expected to Enter Clinical Trials in 2024
15 Nov 2023 //
BUSINESSWIRE
Repare Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
07 Nov 2023 //
BUSINESSWIRE
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
06 Nov 2023 //
BUSINESSWIRE
Repare Announces Positive Data from Phase 1 Trial Evaluating Lunresertib
13 Oct 2023 //
BUSINESSWIRE
Repare to Host Conference to Discuss Ph 1 MYTHIC Modules 1 and 2 Clinical Data
03 Oct 2023 //
BUSINESSWIRE
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data
19 Sep 2023 //
BUSINESSWIRE
Repare to Participate at the Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
BUSINESSWIRE
Repare Therapeutics Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Repare to Participate at Goldman Sachs 44th Annual Global Healthcare Conference
08 Jun 2023 //
BUSINESSWIRE
Repare Therapeutics Reports Proof of Concept for Lunresertib in Clinic
07 Jun 2023 //
BUSINESSWIRE
Repare Therapeutics Announces Publication Highlighting Benefit of Camonsertib
06 Jun 2023 //
BUSINESSWIRE
Repare to Host Conference to Discuss Initial RP-6306 Monotherapy Data
02 Jun 2023 //
BUSINESSWIRE
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 May 2023 //
BUSINESSWIRE
Repare Therapeutics Provides Business Update and Reports1Q 2023 FYR
09 May 2023 //
BUSINESSWIRE
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
28 Apr 2023 //
BUSINESSWIRE
Repare Therapeutics Announces Presentation at AACR on Camonsertib
14 Mar 2023 //
BUSINESSWIRE
Repare Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
BUSINESSWIRE
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
02 Feb 2023 //
BUSINESSWIRE
Repare Therapeutics Receives $1.5M Payment from Ono Pharmaceuticals
19 Jan 2023 //
BUSINESSWIRE
Repare Therapeutics Receives $1.5M Ono Research Payment
19 Jan 2023 //
CONTRACT PHARMA
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
19 Dec 2022 //
BUSINESSWIRE
Repare Therapeutics Provides Business Update and Reports 3Q 2022 Results
09 Nov 2022 //
BUSINESSWIRE
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
07 Nov 2022 //
BUSINESSWIRE
Repare Therapeutics Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Repare Therapeutics to Participate at the Goldman Sachs Healthcare Conference
07 Jun 2022 //
BUSINESSWIRE
Repare Therapeutics to Participate at the Goldman Sachs
07 Jun 2022 //
PRESS RELEASE
Repare Tx Enters WW License and Collaboration Agreement with Roche
01 Jun 2022 //
BUSINESSWIRE
Repare Therapeutics Shares Rise 13% After BVF Partners Upgrades Stake
23 May 2022 //
MORNINGSTAR
Repare Therapeutics (RPTX) Stock: Why The Price Went Up 10.3% Today
23 May 2022 //
PULSE2
Repare Therapeutics to Participate at 2022 Guggenheim Synthetic Lethality Day
09 May 2022 //
BUSINESSWIRE
Repare Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Repare Tx Announces Publication of Preclinical Data on RP-6306 in Tumors
20 Apr 2022 //
BUSINESSWIRE
Repare Tx Presents Updated Data from PI/II TRESR Study of RP-3500 Monotherapy
11 Apr 2022 //
BUSINESSWIRE
